Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven ...

Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...

Experts at Crowe Life Sciences offer tips for effectively managing risk associated with third parties such as clinics, retail ...

Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...

Evaluate VP of Thought Leadership Daniel Chancellor discusses trends for 2025 as the surge in R&D, coupled with rapidly ...

Greenphire’s network of over 90 Concierge Coordinators across 40+ countries provides personalized travel and logistical support to clinical trial participants, ensuring patient comfort and engagement ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

Woody Bryan, Ph.D. has founded several biotech companies during his career, and he explains how his journey from scientist to business development prepared him for the C-suite.

Allan Shaw explains how the incoming Republican administration and Congress may affect the industry, including the Biosecure Act and a change of leadership for the FTC.